Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
LTRN | US
0.05
1.24%
Healthcare
Biotechnology
30/06/2024
30/08/2024
4.09
4.07
4.11
3.92
Lantern Pharma Inc. a clinical stage biotechnology company focuses on artificial intelligence machine learning and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284 a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma. In addition it offers LP-184 an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further the company operates ADC program an antibody drug conjugate therapeutic approach for cancer treatment. Additionally the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas Texas.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
76.3%1 month
89.4%3 months
76.6%6 months
124.6%-
-
1.42
0.01
0.01
0.21
-
-
-19.53M
44.03M
44.03M
-
-
-
-
-44.82
3.97
2.46
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.87
Range1M
1.58
Range3M
3.10
Rel. volume
0.43
Price X volume
106.70K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Rallybio Corporation Common Stock | RLYB | Biotechnology | 1.15 | 47.71M | -3.36% | n/a | 0.35% |
Fortress Biotech Inc | FBIO | Biotechnology | 2.03 | 46.31M | -0.98% | n/a | 494.61% |
LAVA Therapeutics BV | LVTX | Biotechnology | 1.75 | 46.02M | -4.37% | n/a | 14.37% |
Akari Therapeutics Plc | AKTX | Biotechnology | 3.83 | 45.78M | 0.52% | n/a | -27.01% |
CALC | CALC | Biotechnology | 4.17 | 44.83M | -3.02% | n/a | 0.00% |
Aadi Bioscience Inc | AADI | Biotechnology | 1.81 | 44.55M | 3.43% | n/a | 1.34% |
CARM | CARM | Biotechnology | 1.07 | 44.45M | -1.83% | n/a | 0.00% |
Syros Pharmaceuticals Inc | SYRS | Biotechnology | 1.64 | 43.97M | -1.20% | n/a | -954.99% |
Kezar Life Sciences Inc | KZR | Biotechnology | 0.6006 | 43.82M | 0.43% | n/a | 0.00% |
PASSAGE BIO INC. | PASG | Biotechnology | 0.7006 | 43.27M | -5.96% | n/a | 0.00% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 3.68 | 39.85M | -1.12% | n/a | 54.96% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 2.34 | 28.51M | 13.04% | n/a | 16.03% |
ILAG | ILAG | Building Products & Equipment | 1.25 | 22.57M | 6.84% | n/a | 5.48% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 0.6131 | 18.67M | -4.20% | n/a | 204.46% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2495 | 3.93M | 5.94% | n/a | 0.00% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.391 | 3.72M | -6.28% | n/a | 19.98% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.45 | 3.70M | 13.28% | n/a | 9.62% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 2.47 | 2.11M | -7.84% | n/a | 0.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.21 | 0.97 | Cheaper |
Ent. to Revenue | - | 3,681.29 | - |
PE Ratio | - | 39.83 | - |
Price to Book | 1.42 | 14.54 | Cheaper |
Dividend Yield | - | 2.19 | - |
Std. Deviation (3M) | 76.60 | 76.13 | Par |
Debt to Equity | 0.01 | -2.05 | Expensive |
Debt to Assets | 0.01 | 0.25 | Cheaper |
Market Cap | 44.03M | 4.04B | Emerging |